• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
Citation: SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
shu

Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance

More Information
    Graphical Abstract
    • Abstract
  • Poly(ADP-ribose)polymerase-1(PARP-1)plays a vital role in the regulation of DNA repair and apoptosis. Breakthrough has been made in the treatment of cancer with PARP-1 inhibitors, but the emergence of drug resistance has limited its further application in clinic. This paper reviews advances in the research on PARP-1 inhibitors combined with other drugs to overcome drug resistance, highlights and evaluates the existing drug combination strategies and their therapeutic effects in clinical practice. It is proposed that the development of dual-target or multi-target drugs will become a promising approach to overcome the resistance of PARP-1 inhibitors and broaden their indications.
    • FullText(HTML)
    • References (56)
  • [1]
    Vyas S,Chang P.New PARP targets for cancer therapy[J].Nat Rev Cancer,2014,14(7):502-509.
    [2]
    Krishnakumar R, Kraus WL. The PARP side of the nucleus:molecular actions,physiological outcomes,and clinical targets[J].Mol Cell,2010,39(1):8-24.
    [3]
    Miwa M,Masutani M.Poly ADP-ribosylation and cancer[J].Cancer Sci,2007,98(10):1528-1535.
    [4]
    Chen A.PARP inhibitors:its role in treatment of cancer[J].Chin J Cancer,2011,30(7):463-471.
    [5]
    Lord CJ, Ashworth A. The DNA damage response and cancer therapy[J].Nature,2012,481(7381):287-294.
    [6]
    Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors[J].Cancer Res,2012,72(21):5588-5599.
    [7]
    Zhao N,Sun HB.Poly(ADP-ribose)polymerase inhibitors and synthetic lethality[J].J China Pharm Univ(中国药科大学学报),2012,43(2):107-112.
    [8]
    Wang YQ,Wang PY,Wang YT,et al.An update on poly(ADP-ribose)polymerase-1(PARP-1)inhibitors:opportunities and challenges in cancer therapy[J].J Med Chem,2016,59(21):9575-9598.
    [9]
    Damia G, D′Incalci M. Targeting DNA repair as a promising approach in cancer therapy[J].Eur J Cancer,2007,43(12):1791-1801.
    [10]
    Peralta-Leal A,Rodríguez-Vargas JM,Aguilar-Quesada R,et al.PARP inhibitors:new partners in the therapy of cancer and inflammatory diseases[J].Free Radic Biol Med,2009,47(1):13-26.
    [11]
    Konstantinopoulos PA,Ceccaldi R,Shapiro GI,et al.Homologous recombination deficiency:exploiting the fundamental vulnerability of ovarian cancer[J].Cancer Discov,2015,5(11):1137-1154.
    [12]
    Lord CJ,Ashworth A.Mechanisms of resistance to therapies targeting BRCA-mutant cancers[J].Nat Med,2013,19(11):1381-1388.
    [13]
    Bunting SF,Callén E,Wong N,et al.53BP1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks[J].Cell,2010,141(2):243-254.
    [14]
    Bouwman P,Aly A,Escandell JM,et al.53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers[J].Nat Struct Mol Biol,2010,17(6):688-695.
    [15]
    Xu GT,Chapman JR,Brandsma I,et al.REV7 counteracts DNA double-strand break resection and affects PARP inhibition[J].Nature,2015,521(7553):541-544.
    [16]
    Boersma V,Moatti N,Segura-Bayona S,et al.MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′end resection[J].Nature,2015,521(7553):537-540.
    [17]
    Choi YH,Yu AM.ABC transporters in multidrug resistance and pharmacokinetics,and strategies for drug development[J].Curr Pharm Des,2014,20(5):793-807.
    [18]
    Rottenberg S,Jaspers JE,Kersbergen A,et al.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs[J].Proc Natl Acad Sci U S A,2008,105(44):17079-17084.
    [19]
    Oplustilova L,Wolanin K,Mistrik M,et al.Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment[J].Cell Cycle,2012,11(20):3837-3850.
    [20]
    Vaidyanathan A,Sawers L,Gannon AL,et al.ABCB1(MDR1)induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells[J].Br J Cancer,2016,115(4):431-441.
    [21]
    BiPar sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium[J].Cancer Biol Ther,2009,8(1):2-3.
    [22]
    Kummar S,Ji JP,Morgan R,et al.A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas[J].Clin Cancer Res,2012,18(6):1726-1734.
    [23]
    Kummar S,Chen A,Ji JP,et al.Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas[J].Cancer Res,2011,71(17):5626-5634.
    [24]
    Samol J,Ranson M,Scott E,et al.Safety and tolerability of the poly(ADP-ribose)polymerase(PARP)inhibitor,olaparib(AZD2281)in combination with topotecan for the treatment of patients with advanced solid tumors:a phase I study[J].Invest New Drugs,2012,30(4):1493-1500.
    [25]
    Neri P,Ren L,Gratton K,et al.Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors[J].Blood,2011,118(24):6368-6379.
    [26]
    Grünwald V,Merseburger AS.The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors:is there more to come[J]?Eur J Cancer,2013,49(11):2504-2511.
    [27]
    Lee JM,Trepel JB,Choyke P,et al.CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer:biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer[J].Front Oncol,2015,5:123.
    [28]
    Liu JF,Tolaney SM,Birrer M,et al.A phase 1 trial of the poly(ADP-ribose)polymerase inhibitor olaparib(AZD2281)in combination with the anti-angiogenic cediranib(AZD2171)in recurrent epithelial ovarian or triple-negative breast cancer[J].Eur J Cancer,2013,49(14):2972-2978.
    [29]
    Gelmon KA,Tischkowitz M,MacKay H,et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer:a phase 2,multicentre,open-label,non-randomised study[J].Lancet Oncol,2011,12(9):852-861.
    [30]
    Liu JF,Barry WT,Birrer M,et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:a randomised phase 2 study[J].Lancet Oncol,2014,15(11):1207-1214.
    [31]
    Lim S,Kaldis P.Cdks,cyclins and CKIs:roles beyond cell cycle regulation[J].Development,2013,140(15):3079-3093.
    [32]
    Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy[J].Nat Rev Drug Discov,2015,14(2):130-146.
    [33]
    Cicenas J,Kalyan K,Sorokinas A,et al.Highlights of the latest advances in research on CDK inhibitors[J].Cancers(Basel),2014,6(4):2224-2242.
    [34]
    Canavese M,Santo L,Raje N.Cyclin dependent kinases in cancer[J].Cancer Biol Ther,2012,13(7):451-457.
    [35]
    Blazek D,Kohoutek J,Bartholomeeusen K,et al.The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes[J].Genes Dev,2011,25(20):2158-2172.
    [36]
    Liang KW,Gao X,Gilmore JM,et al.Characterization of human cyclin-dependent kinase 12(CDK12)and CDK13 complexes in C-terminal domain phosphorylation,gene transcription,and RNA processing[J].Mol Cell Biol,2015,35(6):928-938.
    [37]
    Joshi PM,Sutor SL,Huntoon CJ,et al.Ovarian cancer-associated mutations disable catalytic activity of CDK12,a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose)polymerase inhibitors[J].J Biol Chem,2014,289(13):9247-9253.
    [38]
    Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer[J].Cell Rep,2016,17(9):2367-2381.
    [39]
    Lim E,Johnson SF,Geyer M,et al.Sensitizing HR-proficient cancers to PARP inhibitors[J].Mol Cell Oncol,2017,4(6):e1299272.doi: 10.1080/23723556.2017.1299272.
    [40]
    Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer[J].Cell Rep,2016,17(9):2367-2381.
    [41]
    Johnson N,Cai DP,Kennedy RD,et al.Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage[J].Mol Cell,2009,35(3):327-339.
    [42]
    Johnson N,Li YC,Walton ZE,et al.Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition[J].Nat Med,2011,17(7):875-882.
    [43]
    Bolin C, Boudra MT, Fernet M, et al. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose)polymerase activity and responses to radiation[J].Cell Mol Life Sci,2012,69(6):951-962.
    [44]
    Tominaga Y,Li CL,Wang RH,et al.Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development[J].Int J Biol Sci,2006,2(4):161-170.
    [45]
    Karnak D,Engelke CG,Parsels LA,et al.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer[J].Clin Cancer Res,2014,20(19):5085-5096.
    [46]
    Garcia TB, Snedeker JC, Baturin D, et al. A small-molecule inhibitor of WEE1,AZD1775,synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia[J].Mol Cancer Ther,2017,16(10):2058-2068.
    [47]
    Parsels LA,Karnak D,Parsels JD,et al.PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors[J].Mol Cancer Res,2018,16(2):222-232.
    [48]
    Kumar A,Fernandez-Capetillo O,Fernadez-Capetillo O,et al.Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair[J].Proc Natl Acad Sci U S A,2010,107(16):7491-7496.
    [49]
    Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition[J].Cancer Discov,2012,2(11):1036-1047.
    [50]
    Wang D,Li CB,Zhang Y,et al.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes[J].Gynecol Oncol,2016,142(3):548-556.
    [51]
    Juvekar A,Burga LN,Hu H,et al.Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer[J].Cancer Discov,2012,2(11):1048-1063.
    [52]
    Sun CY,Fang Y,Yin J,et al.Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers[J].Sci Transl Med,2017,9(392):eaal5148.
    [53]
    Medová M,Aebersold DM,Zimmer Y.MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks[J].Int J Cancer,2012,130(3):728-734.
    [54]
    Du Y,Yamaguchi H,Wei YK,et al.Corrigendum:Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors[J].Nat Med,2016,22(10):1192.
    [55]
    Henneman L,van Miltenburg MH,Michalak EM,et al.Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer[J].Proc Natl Acad Sci U S A,2015,112(27):8409-8414.
    [56]
    Sun Y,Carlson JH,Lin X,et al.Abstract P3-14-08:Preclinical efficacy of targeting c-MET by ARQ197 in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines[C]//Poster Session Abstracts,American Association for Cancer Research,2016.
    • Related Articles

  • Related Articles

    [1]LI Hongxue, ZHANG Lei. Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014[J]. Journal of China Pharmaceutical University, 2016, 47(2): 247-250. DOI: 10.11665/j.issn.1000-5048.20160220
    [2]MAO Dan. Patent analysis of pharmaceutical cocrystals technology in China[J]. Journal of China Pharmaceutical University, 2015, 46(4): 509-512. DOI: 10.11665/j.issn.1000-5048.20150421
    [3]WANG Jingjing, WANG Huiyan, ZHANG Lingling, XIAO Jing, HU Weiguo, ZHANG Caixia, ZHOU Jie. Technical analysis of low molecule weight heparins patents and R&D suggestions[J]. Journal of China Pharmaceutical University, 2015, 46(4): 504-508. DOI: 10.11665/j.issn.1000-5048.20150420
    [4]X-Ray Diffraction Fourier Fingerprint Pattern Analysis for Qingkailing Patent Medicine[J]. Journal of China Pharmaceutical University, 2004, (2): 41-43.
    [5]Study on Related Substances and Stability of Ceftazidime and its Preparation[J]. Journal of China Pharmaceutical University, 2002, (2): 35-38.
    [6]System Separation of Cyclosporin A Triple Therapeutic Drugs by Micellar Electrokinetic Capillary Chromatography and Evaluation of Optimal Method Ruggedness[J]. Journal of China Pharmaceutical University, 1999, (5): 373-376.
    [7]HPLC Analysis of Metoprolol and Its Metabolites in the Perfusates[J]. Journal of China Pharmaceutical University, 1997, (6): 31-35.
    [8]NMR Analysis of Bromocriptine Mesilate Tenoxicam[J]. Journal of China Pharmaceutical University, 1997, (5): 33-35.
    [9]Studies on the Synthesis and Analysis of Impurities and Decomposition Product of Ondansetron Hydrochlorid[J]. Journal of China Pharmaceutical University, 1997, (4): 8-10.
    [10]The Preparation and Analysis of New Sweetener L-Asp-D-Ala-OiPr[J]. Journal of China Pharmaceutical University, 1997, (2): 114-115.

Catalog

    Get Citation
    PDF
    XML
    Article views (784) PDF downloads (1553) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365740

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return